Target intelligence / Profile preview

Homeobox protein aristaless-like 4 (ALX4)

Target
ALX4
Molecular classification
Transcription factor, Homeodomain protein, Paired-like homeodomain transcription factor, Aristaless-related family
01

Overview

Homeobox protein aristaless-like 4 (ALX4) is a member of the aristaless-related class of paired-type homeodomain transcription factors expressed predominantly in the mesenchyme of developing bones, limb buds, craniofacial structures, hair, teeth, and mammary tissue. It binds DNA to regulate the expression of genes essential for embryonic patterning, particularly in the skull and limbs, by controlling cell proliferation, differentiation, and migration. Mutations in ALX4 result in congenital disorders such as enlarged parietal foramina-2 and frontonasal dysplasia type 2, manifesting as defects in cranial bone ossification, midface anomalies, polydactyly, alopecia, and hypogonadism. ALX4 does not currently serve as a therapeutic target for pharmacologic intervention; rather, its clinical relevance is primarily in genetic diagnosis and counseling for developmental syndromes associated with its mutations.

Other names
ALX homeobox 4KIAA1788FPPPFMCRS5FND2homeodomain transcription factor ALX4aristaless-like homeobox 4
02

Mechanism of action

Not applicable (no known drugs directly target ALX4)

03

Biological functions

Regulation of craniofacial and limb developmentRegulation of cell proliferation, differentiation, migration, and survival during embryogenesisEstablishment of anteroposterior polarity in limb budsPatterning of skeletal structures (skull, face, limb buds)
04

Disease associations

Craniofacial malformations (e.g., frontonasal dysplasia)Enlarged parietal foramina (PFM2)PolydactylyAlopecia and hypogonadism when mutatedOther congenital skeletal abnormalities
05

Safety considerations

Not applicable (as it is not a druggable target in current therapy); mutations lead to developmental defects but no known therapeutic safety issues
06

Biomarkers

Genetic variants/mutations in ALX4 are used for diagnosis of parietal foramina type 2 and frontonasal dysplasia type 2

Beyond the preview

Go deeper on Homeobox protein aristaless-like 4 (ALX4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Homeobox protein aristaless-like 4 (ALX4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call